Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BVXV BiondVax Pharmaceuticals (BVXV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About BiondVax Pharmaceuticals Stock (NASDAQ:BVXV) 30 days 90 days 365 days Advanced Chart Ad WealthPressThe Tesla Trade Is Back In BusinessIf you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Get BVXV alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.26▼$1.5952-Week Range N/AVolume23,000 shsAverage Volume127,289 shsMarket Capitalization$2.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.Read More… The Tesla Trade Is Back In Business (Ad)If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Receive BVXV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BVXV Stock News HeadlinesBiondVax Pharmaceuticals (NASDAQ: BVXV)May 8, 2024 | fool.comSCNI Scinai Immunotherapeutics Ltd.March 23, 2024 | seekingalpha.comStrange: Why is Amazon suddenly yielding 39.70%?Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%!November 17, 2024 | Investors Alley (Ad)Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023October 4, 2023 | finance.yahoo.comScinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct OfferingSeptember 19, 2023 | finance.yahoo.comScinai Immunotherapeutics Announces $1.33 Million Registered Direct OfferingSeptember 15, 2023 | finance.yahoo.comScinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical ResultsSeptember 13, 2023 | finance.yahoo.comScinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in BostonSeptember 11, 2023 | finance.yahoo.comSee More Headlines BVXV Stock Analysis - Frequently Asked Questions How were BiondVax Pharmaceuticals' earnings last quarter? BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) issued its quarterly earnings results on Monday, March, 28th. The company reported ($2.70) earnings per share for the quarter, missing the consensus estimate of ($0.90) by $1.80. When did BiondVax Pharmaceuticals' stock split? BiondVax Pharmaceuticals's stock reverse split on Friday, November 25th 2022. The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did BiondVax Pharmaceuticals IPO? BiondVax Pharmaceuticals (BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp acted as the underwriter for the IPO. What other stocks do shareholders of BiondVax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that BiondVax Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Corbus Pharmaceuticals (CRBP) and Pluristem Therapeutics (PSTI). Company Calendar Last Earnings3/28/2022Today11/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:BVXV CUSIPN/A CIK1611747 Webwww.biondvax.com Phone9723029302529Fax972-8930-2531Employees33Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-346.36% Return on Assets-29.52% Debt Debt-to-Equity RatioN/A Current Ratio4.12 Quick Ratio4.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($3.81) per share Price / BookN/AMiscellaneous Outstanding Shares1,870,000Free Float1,755,000Market Cap$2.54 million OptionableNot Optionable Beta2.37 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:BVXV) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiondVax Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BiondVax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
